THOMAS HOFSTAETTER, PH.D. - Corporate Board Profile

GERON CORP

Filing Date	Source Excerpt
2010-03-29	Thomas Hofstaetter, Ph.D., has served as a director of the Company since March 2010 and is currently President, Chief Executive Officer and a director of VaxInnate Corporation, ... The Compensation Committee, which was comprised of Dr. Barkas and Mr. Zenner, met three times in 2009 and acted by written consent on eight occasions. Currently, the Compensation Committee is comprised of Drs. Barkas and Hofstaetter and Mr. Zenner. ... Dr. Hofstaetter joined the Board in March 2010.
2011-03-28	Thomas Hofstaetter, Ph.D., has served as a director of the Company since March 2010. The Compensation Committee, which is currently comprised of Drs. Barkas and Hofstaetter. The following table provides compensation information for the year ended December 31, 2010 for each non-employee member of the Board. Hofstaetter, Thomas $ 10,333 58,602 157,156 226,091
2012-04-03	Thomas Hofstaetter, Ph.D., has served as a director of the Company since March 2010... The Compensation Committee, which is comprised of Drs. Hofstaetter, Lawlis (who joined in March 2012) and Spiegel, met seven times in 2011... The Board believes Dr. Hofstaetter's expertise... qualifies Dr. Hofstaetter to be nominated as a director. Director Compensation Table shows total compensation of $136,064.
2013-04-05	Thomas Hofstaetter, Ph.D., has served as a director of Geron since March 2010. ... The Board believes Dr. Hofstaetter's expertise with numerous technology transactions ... qualifies Dr. Hofstaetter to serve as a director. ... The Compensation Committee, which is comprised of Drs. Hofstaetter, Lawlis (who joined in March 2012) and Spiegel, met 12 times in 2012. ... The following table provides compensation information for the fiscal year ended December 31, 2012 for each non-employee member of the Board. ... Hofstaetter, Thomas $60,791 in fees and $28,424 in option awards totaling $89,215.
2014-04-04	Thomas Hofstaetter, Ph.D., has served as a director of Geron since March 2010. Dr. Hofstaetter also serves as a director for BioAlliance Pharma SA, a French company focused on drugs for the treatment of cancer and orphan-status diseases. Dr. Hofstaetter was President, Chief Executive Officer and a director of VaxInnate Corporation, a privately-held biotechnology vaccine company, from January 2010 to December 2011. From September 2004 to October 2009, Dr. Hofstaetter was Senior Vice President, Corporate Development and Head of Global Business Development and a member of the Wyeth Management Committee at Wyeth, Inc., a global pharmaceutical company. At Wyeth, he closed more than 70 transactions, including acquisitions of biotechnology companies, in-licensing of products and broad technology collaborations. From December 1999 to August 2004, Dr. Hofstaetter was Senior Vice President of Corporate Development of Aventis, a global pharmaceutical company. While at Aventis, he was responsible for more than 100 transactions including research alliances, product in- and out-licensing, divestments and spin-outs. In 1978, Dr. Hofstaetter joined Behringwerke AG in Germany as a research scientist and rose to become Head of Research in 1988 and head of the Immunology/Oncology business unit in 1989. From 1991 to 1999, Dr. Hofstaetter served in various executive managerial positions around the world, including the United States, Japan, France and his native Germany, with Hoechst Pharma, a global pharmaceutical company. Dr. Hofstaetter holds a Master of Science degree in biochemistry and a Ph.D. in molecular biology, magna cum laude, from the University of Tuebingen in Germany. The Compensation Committee, which is comprised of Drs. Hofstaetter, Lawlis and Spiegel, met seven times in 2013. Each of the members of the Compensation Committee is "independent," as required by NASDAQ Rules 5605(a)(2) and 5605(d)(2). In determining whether Drs. Hofstaetter, Lawlis and Spiegel are independent within the meaning of NASDAQ Rules pertaining to membership of the Compensation Committee that will be in effect for us as of the Annual Meeting, our Board determined, based on its consideration of factors specifically relevant to determining whether any such director has a relationship to us that is material to that director's ability to be independent from management in connection with the duties of a compensation committee member, that no member of the Compensation Committee has a relationship that would impair that member's ability to make independent judgments about our executive compensation. The Compensation Committee's responsibilities include making recommendations concerning compensation of executive officers, administering Geron's incentive compensation and benefit plans, and performing such other functions regarding compensation as the Board may delegate. The following table provides compensation information for the fiscal year ended December 31, 2013, or fiscal 2013, for each non-employee member of the Board who served in such capacity during fiscal 2013. Dr. Scarlett does not receive any compensation for his Board service. The following table sets forth the following information with respect to non-employee directors (nine persons) for the fiscal year ended December 31, 2013: (i) stock options granted under the 2006 Directors' Plan; and (ii) the grant date fair value of stock options granted.